Latest: FDA Approves New Biosimilar for Oncology Treatment

Targeting SIGLEC10 With ONC-841: A Novel Mechanism in Alzheimer Disease Treatment

by Neurology Live

13 September, 2025

0 Mins

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC-841, a novel anti-SIGLEC10 antibody targeting amyloid and tau in Alzheimer disease.

Tags:

Author

Neurology Live

iPSC protocol opens the door to explore male infertility treatments

Overweight body habitus is associated with higher rates of relapse in children with acute lymphoblastic leukemia

📢

300x250 Banner

Targeting SIGLEC10 With ONC-841: A Novel Mechanism in Alzheimer Disease Treatment

Tags:

Neurology Live

iPSC protocol opens the door to explore male infertility treatments

Overweight body habitus is associated with higher rates of relapse in children with acute lymphoblastic leukemia

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition